Publications by authors named "Jonathan LoPresti"

Claim this Profile
I
Influence of Thyroglobulin Autoantibodies on Thyroglobulin Levels Measured by Different Methodologies: IMA, LC-MS/MS, and RIA.
Ivana Petrovic, Jonathan LoPresti, Shireen Fatemi, Andrew Gianoukakis, Kenneth Burman

J Clin Endocrinol Metab· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does Reverse Triiodothyronine Testing Have Clinical Utility? An Analysis of Practice Variation Based on Order Data from a National Reference Laboratory.
Robert L Schmidt, Jonathan S LoPresti, Michael T McDermott, Suzanna M Zick, Joely A Straseski

Thyroid· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study.
Trevor E Angell, Melissa G Lechner, Caroline T Nguyen, Victoria L Salvato, John T Nicoloff, Jonathan S LoPresti

J Clin Endocrinol Metab· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications.
Carole Spencer, Ivana Petrovic, Shireen Fatemi, Jonathan LoPresti

J Clin Endocrinol Metab· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.
Trevor E Angell, Melissa G Lechner, Julie K Jang, Jonathan S LoPresti, Alan L Epstein

Clin Cancer Res· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is an isolated TSH elevation in chronic nonthyroidal illness "subclinical hypothyroidism"?
Elaine M Kaptein, Jonathan S LoPresti, Matthew J Kaptein

J Clin Endocrinol Metab· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies.
Carole Spencer, Jonathan LoPresti, Shireen Fatemi

Curr Opin Endocrinol Diabetes Obes· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.
Trevor E Angell, Melissa G Lechner, Julie K Jang, Adrian J Correa, Jonathan S LoPresti

Thyroid· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation.
Trevor E Angell, Carole A Spencer, Barbara D Rubino, John T Nicoloff, Jonathan S LoPresti

Thyroid· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer.
Carole Spencer, Shireen Fatemi, Peter Singer, John Nicoloff, Jonathan Lopresti

Thyroid· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer.
Carole A Spencer, Jonathan S Lopresti

Nat Clin Pract Endocrinol Metab· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
Shireen Fatemi, Jonathan S LoPresti

J Clin Endocrinol Metab· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis